Press coverage about LivaNova (NASDAQ:LIVN) has trended somewhat positive recently, according to Accern Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. LivaNova earned a news sentiment score of 0.19 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 44.9670092159401 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
LivaNova (NASDAQ LIVN) traded up $0.07 during trading hours on Friday, reaching $80.33. The company had a trading volume of 1,498,567 shares, compared to its average volume of 395,674. The firm has a market capitalization of $3,932.14, a price-to-earnings ratio of 23.50, a P/E/G ratio of 2.45 and a beta of 0.61. LivaNova has a 1 year low of $44.58 and a 1 year high of $88.56. The company has a current ratio of 2.03, a quick ratio of 1.42 and a debt-to-equity ratio of 0.04.
LivaNova (NASDAQ:LIVN) last released its earnings results on Thursday, November 2nd. The company reported $0.93 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.76 by $0.17. The firm had revenue of $309.70 million for the quarter, compared to analyst estimates of $301.22 million. LivaNova had a return on equity of 9.33% and a net margin of 4.63%. LivaNova’s revenue was up 4.9% compared to the same quarter last year. During the same period in the previous year, the company earned $0.78 earnings per share. equities analysts anticipate that LivaNova will post 3.33 earnings per share for the current fiscal year.
In related news, Director Alfred J. Novak sold 2,000 shares of LivaNova stock in a transaction dated Wednesday, November 22nd. The stock was sold at an average price of $85.77, for a total transaction of $171,540.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Hugh M. Morrison sold 1,830 shares of LivaNova stock in a transaction dated Wednesday, November 29th. The stock was sold at an average price of $88.00, for a total value of $161,040.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 5,830 shares of company stock worth $488,550. 0.28% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: This news story was first posted by Week Herald and is the property of of Week Herald. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://weekherald.com/2017/12/15/livanova-livn-given-news-sentiment-rating-of-0-19.html.
LivaNova Company Profile
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.